POGO Urges Senate to Oppose Obama’s FDA NomineeTweet
February 10, 2016
The Project On Government Oversight wrote to the Senate urging members to oppose President Obama’s nominee to head the Food and Drug Administration (FDA), Dr. Robert Califf. This request comes in light of Califf’s relationship with the pharmaceutical industry and POGO’s own investigations.
As POGO reported in November, Califf co-chaired a faulty clinical trial for the blood thinner Xarelto. An FDA review suggested that “a lack of care” in the trial’s design led to “unnecessary strokes” in test subjects, and voiced concern that the trial put commercial considerations ahead of health and safety.
During his FDA nomination process, Califf answered reassuringly about the input of pharmaceutical sponsors on the design of clinical trials when asked about the subject by Senator Elizabeth Warren (D-MA), but we question the accuracy of his answer.
POGO also wrote to the President urging him to withdraw Califf’s nomination.
Iulia is the Beth Daley Impact fellow at the Project On Government Oversight.
Topics: Public Health and Science
Authors: Iulia Gheorghiu
- January 13, 2017
- January 3, 2017
- December 14, 2016
- December 2, 2016
- November 17, 2016
- October 27, 2016
- October 21, 2016
- September 21, 2016